Literature DB >> 21529954

Evaluation of retinal nerve fiber layer progression in glaucoma: a comparison between spectral-domain and time-domain optical coherence tomography.

Christopher Kai-Shun Leung1, Vivian Chiu, Robert N Weinreb, Shu Liu, Cong Ye, Marco Yu, Carol Yim-Lui Cheung, Gilda Lai, Dennis Shun-Chiu Lam.   

Abstract

OBJECTIVE: To compare the performance of a spectral-domain optical coherence tomography (OCT) device and a time-domain OCT device to detect retinal nerve fiber layer (RNFL) progression in glaucoma patients.
DESIGN: Prospective study. PARTICIPANTS: One hundred twenty-eight eyes of 81 glaucoma patients.
METHODS: Patients were followed up at 4-month intervals for at least 24 months for RNFL imaging and visual field examination. Both eyes were imaged by the Cirrus HD-OCT (Carl Zeiss Meditec, Inc., Dublin, CA) and the Stratus OCT (Carl Zeiss Meditec, Inc.) and underwent visual field testing at the same visit. Linear regression analyses between circumpapillary RNFL measurements (average, superior, and inferior RNFL thicknesses), visual field index (VFI), and follow-up time were performed. RNFL progression and RNFL improvement were identified when a significant negative or positive trend was detected, respectively. The agreement between the OCT instruments for progression detection was analyzed with κ statistics. MAIN OUTCOME MEASURES: Number of eyes with RNFL progression and improvement, agreement of progression detection between RNFL measurements and VFI, and rate of change of average RNFL thickness.
RESULTS: Twenty-two eyes (19 patients) and 4 eyes (4 patients) had progression, and 0 and 5 eyes (5 patients) had improvement detected by the Cirrus HD-OCT and the Stratus OCT average RNFL measurements, respectively. The agreement for detection of RNFL progression was poor between the 2 OCT instruments (κ = 0.188, 0.027, and 0.267 for average, superior, and inferior RNFL thicknesses, respectively). The respective agreement between VFI and average RNFL thickness progression determined by the Cirrus HD-OCT and the Stratus OCT was 0.125 and 0.047. The rate of average RNFL thickness progression ranged between -1.52 μm/year and -5.03 μm/year for the Cirrus HD-OCT and between -2.22 μm/year and -7.60 μm/year for the Stratus OCT.
CONCLUSIONS: The Cirrus HD-OCT outperformed the Stratus OCT in detecting more eyes with RNFL progression and fewer eyes with RNFL improvement. Because of reduced measurement variability, the Cirrus HD-OCT could detect changes in RNFL thickness sooner than the Stratus OCT. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21529954     DOI: 10.1016/j.ophtha.2011.01.026

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  46 in total

1.  Evaluation of Visual Field and Imaging Outcomes for Glaucoma Clinical Trials (An American Ophthalomological Society Thesis).

Authors:  David F Garway-Heath; Ana Quartilho; Philip Prah; David P Crabb; Qian Cheng; Haogang Zhu
Journal:  Trans Am Ophthalmol Soc       Date:  2017-08-22

2.  Glaucomatous retinal nerve fiber layer thickness loss is associated with slower reaction times under a divided attention task.

Authors:  Andrew J Tatham; Erwin R Boer; Peter N Rosen; Mauro Della Penna; Daniel Meira-Freitas; Robert N Weinreb; Linda M Zangwill; Felipe A Medeiros
Journal:  Am J Ophthalmol       Date:  2014-07-25       Impact factor: 5.258

3.  Comparison of event-based analysis of glaucoma progression assessed subjectively on visual fields and retinal nerve fibre layer attenuation measured by optical coherence tomography.

Authors:  Sushmita Kaushik; Samyak Mulkutkar; Surinder Singh Pandav; Neelam Verma; Amod Gupta
Journal:  Int Ophthalmol       Date:  2014-12-13       Impact factor: 2.031

Review 4.  Parameters of ocular fundus on spectral-domain optical coherence tomography for glaucoma diagnosis.

Authors:  Yu-Lin Tao; Li-Ming Tao; Zheng-Xuan Jiang; He-Ting Liu; Kun Liang; Mo-Han Li; Xuan-Sheng Zhu; Yan-Lin Ren; Bing-Jie Cui
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

5.  Patterns of glaucoma progression in retinal nerve fiber and macular ganglion cell-inner plexiform layer in spectral-domain optical coherence tomography.

Authors:  Hae Jin Kim; Jin Wook Jeoung; Byeong Wook Yoo; Hee Chan Kim; Ki Ho Park
Journal:  Jpn J Ophthalmol       Date:  2017-04-03       Impact factor: 2.447

6.  A new diagnostic model of primary open angle glaucoma based on FD-OCT parameters.

Authors:  Ya-Jie Zheng; Ying-Zi Pan; Xue-Ying Li; Yuan Fang; Mei Li; Rong-Hua Qiao; Yu Cai
Journal:  Int J Ophthalmol       Date:  2018-06-18       Impact factor: 1.779

7.  Retinal nerve fiber layer atrophy is associated with visual field loss over time in glaucoma suspect and glaucomatous eyes.

Authors:  Mitra Sehi; Xinbo Zhang; David S Greenfield; Yunsuk Chung; Gadi Wollstein; Brian A Francis; Joel S Schuman; Rohit Varma; David Huang
Journal:  Am J Ophthalmol       Date:  2012-10-01       Impact factor: 5.258

8.  Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema.

Authors:  Melissa M Liu; Yulia Wolfson; Susan B Bressler; Diana V Do; Howard S Ying; Neil M Bressler
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-06       Impact factor: 4.799

9.  Retinal nerve fibre layer thickness floor and corresponding functional loss in glaucoma.

Authors:  Jean-Claude Mwanza; Donald L Budenz; Joshua L Warren; Aaron D Webel; Courtney E Reynolds; Diego T Barbosa; Shan Lin
Journal:  Br J Ophthalmol       Date:  2014-12-09       Impact factor: 4.638

10.  Discrepancy between optic disc and nerve fiber layer assessment and optical coherence tomography in detecting glaucomatous progression.

Authors:  Jong Rak Lee; Kyung Rim Sung; Jung Hwa Na; Kilhwan Shon; Kyoung Sub Lee
Journal:  Jpn J Ophthalmol       Date:  2013-10-05       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.